Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan
Our Clinical Development Pipeline is focused on discovering and developing innovative drugs for indications
Our mission is to become a fully-integrated international biopharmaceutical company, leveraging our deep experience in RNA therapeutics and novel delivery platform technologies to rapidly discover and develop innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics.